BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Dec 12, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Eylea aflibercept ophthalmic solution: Phase III started

Bayer's Bayer Healthcare AG subgroup began the double-blind, Chinese Phase III SIGHT trial in about 300 patients to compare 2 mg intravitreal Eylea given monthly for the first 3 months and every 2 months thereafter vs. Visudyne verteporfin for 48 weeks....

Read the full 191 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >